About this item:

144 Views | 212 Downloads

Author Notes:

Corresponding author: Laurence W. Busse. lbusse@emory.edu

All authors were major contributors in writing the manuscript. All authors read and approved the final manuscript.

JHC serves on the Speaker’s Bureau for La Jolla Pharmaceutical Company.

All other authors report no competing interests.


Research Funding:

The authors received no funding related to this manuscript.


  • ACE2
  • Angiotensin II
  • COVID-19
  • Coronavirus
  • RAAS
  • Angiotensin II
  • Angiotensin-Converting Enzyme Inhibitors
  • Betacoronavirus
  • Coronavirus Infections
  • Humans
  • Pandemics
  • Pneumonia, Viral
  • Renin-Angiotensin System

COVID-19 and the RAAS-a potential role for angiotensin II?


Journal Title:

Critical Care


Volume 24, Number 1


, Pages 136-136

Type of Work:

Article | Final Publisher PDF


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease 2019 (COVID-19) have wreaked havoc on healthcare systems globally. The potential for spread of this highly infectious virus, which is more transmissible and lethal than influenza, has reached pandemic proportions and has left many clinicians scrambling to provide care with scarce resources, all in the setting of no curative treatment, immunization, or effective therapy. Some candidate therapies include antivirals (remdesivir), antimalarials (hydroxychloroquine), and vaccines (mRNA-1273). Moreover, as we learn more about this virus, we have begun to draw some noteworthy conclusions regarding currently available ancillary “therapies” which may affect the natural history of the COVID-19 infection. Some of these “therapies” may actually be the avoidance of certain medications, like ibuprofen. Likewise, patients on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) could be at a greater risk due to the mechanism by which SARS-CoV-2 enters the cell. It stands to reason that therapeutics that act counter to this mechanism may confer protection.

Copyright information:

© The Author(s) 2020

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote